MARKET WIRETradingKey • 9h ago
Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the MovementTradingKey report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
Why NVS Stock slipped -0.19% Today — RQD Quant Desk Flash
$160.79 -0.19% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $160.43
Novartis AG (NVS) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $307.40B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NVS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Novartis AG (NYSE: NVS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $160.79 (-0.19% 1D, market cap $307.40B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, NVS ranks #113 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NVS compare to AZN and MRK in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVS carries a Roarable C+ (66/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, AZN (AstraZeneca PLC) holds a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $270.45B) and MRK (Merck & Company Inc.) posts a B grade (75/100 RQD, P/E 19.8x, ROIC 20.7%, cap $361.02B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NVS?
▼
For Novartis AG (NVS), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $160.44 (-0.22%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 15.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY • 56.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+3.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NVS)Realized 20D OHLCV Swing Band: ±3.9%
Deterministic 5-Pillar Attribution (66/100 Composite)
🔍 WHY NVS SCORES 66/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (24% of score)
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (23% of score)
20D Institutional Volume Accumulation (±3.9% realized swing band)
▼ #1 Drag / Risk Factor: Cash Engine Quality11/20 pts (-9 pt drag)
Capital intensity & 13.9% operating margin leave 9 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$142.41+7.9% Next Q
58
Q2 (-2Q)Grade C$153.64+2.1% Next Q
61
Q3 (-1Q)Grade C+$156.86+2.5% Next Q
63
CurrentGrade C+$160.79+1.4% Hist 90D α
66
Trajectory: C (58) → C+ (66)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the NVS Bull Thesis Could Fail
Even with a 66/100 (C+) score, NVS faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($148.51) or 200D SMA ($151.98) invalidates the momentum regime and cuts Target Base ($166.58) toward Bear Floor ($129.93).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NVS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NVS Stock slipped -0.19% Today — RQD Quant Desk Flash
Novartis AG (NVS) slipped -0.19% to $160.79, trading at 80% of its 52-week range ($122.86 – $170.46). Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 80% of its 52-week range ($122.86 – $170.46) with RSI-14 at 69.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±3.9% around $160.79 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 52% gross margin and $6.8B annual free cash flow.
Live NVS Headlines & Catalysts
MARKET WIREYahoo Finance • 12h ago
Novartis AG (NVS) Stock ForecastsYahoo Finance report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 15h ago
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100GuruFocus report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 18h ago
Novartis AG 2026 Q3 - Results - Earnings Call Presentation (NYSE:NVS) 2026-10-29Seeking Alpha report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 21h ago
Why Novartis (NVS) Stock Is Up TodayQuiver Quantitative report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9B Avidity Hit - Novartis (NYSE:NVS)Benzinga report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF ScoGuruFocus report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 13h ago
Deutsche Bank turns bearish on Novartis as shares recover failed trial lossesInvesting.com -- Deutsche Bank downgraded pharmaceutical company Novartis to “sell” from “hold” and cut its price target to CHF115 from CHF120, saying the shares have more than recovered losses from two failed drug trial
MARKET WIREBenzinga • 14h ago
Allarity Therapeutics Settles $4.9M Novartis Liability For $1M PaymentOn October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an
MARKET WIREYahoo • 22h ago
Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer TrialNovartis (SWX:NOVN) reported new trial data showing Votrient plus Roche's Avastin improved overall survival in certain advanced kidney cancer patients. The combination delivered overall survival outcomes much greater tha
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (NVS Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.18%📐 HORIZONTAL RANGE
2026-11-02O $156.1H $161.1L $156.1C $160.8VOL 2.24M
RES: $164.0SUP: $134.2SMA50: $148.5SMA200: $152.0
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NVS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NVS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVS)
Health Care Rank #113 of 1016
⚔️ AZN vs NVS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NVS vs. AZN, MRK, ABBV, ABT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Novartis AG (NVS) ranks #113 by composite RQD confidence (66/100, grade C+) and #7 by equity capitalization ($307.40B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. ABBV currently holds the highest overall quantitative score in the immediate peer group at 81/100 (A-) compared with NVS at 66/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NVS
ACTIVE
Novartis AG | C+ | 66/100 | 32.8x | — | 9.9% | -0.19% | $307.40B | Benchmark Subject |
| AZN AstraZeneca PLC | C | 62/100 | 32.8x | — | 9.9% | +7.02% | $270.45B | /azn-vs-nvs → |
| MRK Merck & Company Inc. | B | 75/100 | 19.8x | 74.8% | 20.7% | +2.18% | $361.02B | /mrk-vs-nvs → |
| ABBV AbbVie Inc. | A- | 81/100 | 121.6x | 70.2% | 29.0% | +1.41% | $513.86B | /abbv-vs-nvs → |
| ABT Abbott Laboratories | B+ | 77/100 | 27.7x | 56.4% | 11.9% | +1.56% | $180.95B | /abt-vs-nvs → |
2. NVS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTNovartis AG (NVS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $307.40B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.
3. NVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Novartis AG (NYSE: NVS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $160.79 (-0.19% 1D, market cap $307.40B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, NVS ranks #113 in composite RQD confidence.
How does NVS compare to AZN and MRK in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVS carries a Roarable C+ (66/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, AZN (AstraZeneca PLC) holds a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $270.45B) and MRK (Merck & Company Inc.) posts a B grade (75/100 RQD, P/E 19.8x, ROIC 20.7%, cap $361.02B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NVS?
For Novartis AG (NVS), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NVS trading relative to its 50-day, 200-day, and 52-week technical levels?
NVS last traded at $160.79 (-0.19% on volume of 3,152,901 shares), positioning the stock +8.27% above its 50-day simple moving average ($148.51) and +5.80% above its 200-day simple moving average ($151.98). Across its 52-week range of $122.86 to $170.46, NVS sits at the 79.7% percentile with a 14-day RSI of 69.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±3.9% ($154.52 to $167.06).
NVS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NVS stock moving today?
Why NVS Stock slipped -0.19% Today — RQD Quant Desk Flash. Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 66/100 (C+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
NVS — Novartis AG: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:07:43Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, NVS scores 66 out of 100, a letter grade of C+, with the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." Across the five pillars:
- Fundamental Cash Engine: 11 / 20. Per the RQD rating, this pillar reflects ROIC of 9.9% and an FCF yield of 2.21%. Investor implication: returns on capital are positive but modest, and the cash yield is thin relative to the stock price, so the valuation case depends more on growth expectations than on current cash generation.
- Whale 13F Flow: 15 / 20. Per the RQD rating, this reflects institutional accumulation and options positioning. The underlying 13F and options detail is not itemized in the source data, so the score cannot be traced to specific holders. Investor implication: institutional interest appears constructive but is a moderate contributor to the overall score.
- Insider Conviction: 12 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not provided in the source data. Investor implication: insider signal is neutral-to-mildly-positive and does not by itself drive the verdict.
- Macro Regime Fit: 12 / 20. Per the RQD rating, this reflects beta of 1.05 and sector sensitivity. Investor implication: the stock tends to move roughly in line with the broad market, so it offers little defensive differentiation or outsized high-beta exposure.
- Forensic Balance Sheet: 16 / 20. Per the RQD rating, this reflects Altman Z of 3.74, Piotroski F of 8/9, and Debt/Equity of 0.39. Investor implication: this is the strongest pillar, indicating a financially sound balance sheet with low leverage and strong fundamental health signals.
The overall profile is a balanced, mid-range rating: strong balance-sheet quality offsets thin cash yield and a valuation that the market prices at a premium. The "Watch for Breakout" language in the verdict label signals that the rating is near the threshold where a shift in pillar scores could change the outlook.
Snapshot
Open Questions
- What is the reported revenue, operating income, net income, EPS, free cash flow, cash, and debt trend across recent periods? The financial statements section is empty.
- What is the composition of the $1.9B Avidity hit referenced in the news feed, and how does it affect forward earnings expectations?
- Which institutional holders and insiders account for the accumulation and cluster flows that drive the Whale and Insider pillar scores?
- What analyst consensus rating and price targets exist, and how do they compare to the $161.1 price?
- What drives the 27.6 forward P/E versus the 32.8 trailing P/E, and what earnings growth is implied by that compression?
NVS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Novartis AG (NVS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingKey • 9h ago
Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement TradingKey report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 12h ago
Novartis AG (NVS) Stock Forecasts Yahoo Finance report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 15h ago
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100 GuruFocus report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 18h ago
Novartis AG 2026 Q3 - Results - Earnings Call Presentation (NYSE:NVS) 2026-10-29 Seeking Alpha report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 21h ago
Why Novartis (NVS) Stock Is Up Today Quiver Quantitative report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9B Avidity Hit - Novartis (NYSE:NVS) Benzinga report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Sco GuruFocus report covering Novartis AG (NVS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo • 13h ago
Deutsche Bank turns bearish on Novartis as shares recover failed trial losses Investing.com -- Deutsche Bank downgraded pharmaceutical company Novartis to “sell” from “hold” and cut its price target to CHF115 from CHF120, saying the shares have more than recovered losses from two failed drug trial
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NVS Bull vs. Bear Conversation Board — What's Your Call at $160.79?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NVS 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $173.99 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is NVS (C+ • RQD 66/100) a Buy at $161.10?
Welcome to the NVS (Novartis AG) Roar Pit. Current RQD Composite is 66/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $120.83 (-25.0%)
Spot @ $161.10 Pump the brakes on NVS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on NVS, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Novartis AG expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $206.21 (+28.0%)
Spot @ $161.10 NVS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on NVS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $161.10 (52-wk range $122.86 - $170.46), any beat on forward guidance forces shorts and underweight funds to chase.